UA81491C2 - N-{'4-substituted piperazine-1-sulfonylmethyl]alkyl}-n-hydroxyformamide compounds as metalloproteinase inhibitors, pharmaceutical composition based thereon, proces for the preparation thereof, intermediate (variants) - Google Patents

N-{'4-substituted piperazine-1-sulfonylmethyl]alkyl}-n-hydroxyformamide compounds as metalloproteinase inhibitors, pharmaceutical composition based thereon, proces for the preparation thereof, intermediate (variants) Download PDF

Info

Publication number
UA81491C2
UA81491C2 UAA200511723A UAA200511723A UA81491C2 UA 81491 C2 UA81491 C2 UA 81491C2 UA A200511723 A UAA200511723 A UA A200511723A UA A200511723 A UAA200511723 A UA A200511723A UA 81491 C2 UA81491 C2 UA 81491C2
Authority
UA
Ukraine
Prior art keywords
compound
ring
formula
pharmaceutically acceptable
prodrug
Prior art date
Application number
UAA200511723A
Other languages
English (en)
Ukrainian (uk)
Inventor
David Waterson
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27656653&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=UA81491(C2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of UA81491C2 publication Critical patent/UA81491C2/uk

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/47—One nitrogen atom and one oxygen or sulfur atom, e.g. cytosine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/22—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with hetero atoms directly attached to ring nitrogen atoms
    • C07D295/26—Sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
    • C07D309/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D309/04—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Vascular Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Otolaryngology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyrane Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
UAA200511723A 2003-06-27 2004-06-23 N-{'4-substituted piperazine-1-sulfonylmethyl]alkyl}-n-hydroxyformamide compounds as metalloproteinase inhibitors, pharmaceutical composition based thereon, proces for the preparation thereof, intermediate (variants) UA81491C2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE0301922A SE0301922D0 (sv) 2003-06-27 2003-06-27 Novel compounds
PCT/GB2004/002702 WO2005000822A1 (en) 2003-06-27 2004-06-23 N-{‘4-substituted piperazine-1-sulfonylmethyl!alkyl}-n-hydroxyfomamide compounds as metalloproteinase inhibitors

Publications (1)

Publication Number Publication Date
UA81491C2 true UA81491C2 (en) 2008-01-10

Family

ID=27656653

Family Applications (1)

Application Number Title Priority Date Filing Date
UAA200511723A UA81491C2 (en) 2003-06-27 2004-06-23 N-{'4-substituted piperazine-1-sulfonylmethyl]alkyl}-n-hydroxyformamide compounds as metalloproteinase inhibitors, pharmaceutical composition based thereon, proces for the preparation thereof, intermediate (variants)

Country Status (34)

Country Link
US (1) US7485644B2 (zh)
EP (1) EP1644340B1 (zh)
JP (1) JP4701167B2 (zh)
KR (1) KR20060026440A (zh)
CN (2) CN102229589A (zh)
AR (1) AR044931A1 (zh)
AT (1) ATE414063T1 (zh)
AU (1) AU2004251104B2 (zh)
BR (1) BRPI0411929A (zh)
CA (1) CA2529468A1 (zh)
CO (1) CO5650254A2 (zh)
CY (1) CY1108757T1 (zh)
DE (1) DE602004017733D1 (zh)
DK (1) DK1644340T3 (zh)
ES (1) ES2315675T3 (zh)
HK (1) HK1086835A1 (zh)
HR (1) HRP20090009T3 (zh)
IL (1) IL172615A0 (zh)
IS (1) IS8257A (zh)
MX (1) MXPA05013460A (zh)
MY (1) MY138680A (zh)
NO (1) NO20060444L (zh)
NZ (1) NZ544208A (zh)
PL (1) PL1644340T3 (zh)
PT (1) PT1644340E (zh)
RU (1) RU2351595C2 (zh)
SA (1) SA04250224B1 (zh)
SE (1) SE0301922D0 (zh)
SI (1) SI1644340T1 (zh)
TW (1) TW200524898A (zh)
UA (1) UA81491C2 (zh)
UY (1) UY28387A1 (zh)
WO (1) WO2005000822A1 (zh)
ZA (1) ZA200510458B (zh)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0427403D0 (en) * 2004-12-15 2005-01-19 Astrazeneca Ab Novel compounds I
PL1951674T3 (pl) * 2005-10-26 2012-04-30 Merck Serono Sa Pochodne sulfonamidowe i ich zastosowania do modulowania metaloproteinaz
CN101007794B (zh) * 2006-01-26 2010-09-01 中国科学院上海药物研究所 N,n'-二取代哌嗪类衍生物及其制备方法、药物组合物和用途
WO2009151910A2 (en) * 2008-05-25 2009-12-17 Wyeth Combination product of receptor tyrosine kinase inhibitor and fatty acid synthase inhibitor for treating cancer
CA2804918C (en) * 2010-07-08 2018-03-06 Kaken Pharmaceutical Co., Ltd. N-hydroxyformamide derivative and medicament containing same

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2317455C (en) 1998-01-30 2011-01-25 Darwin Discovery Limited Hydroxamic and carboxylic acid derivatives
GB9919776D0 (en) * 1998-08-31 1999-10-27 Zeneca Ltd Compoujnds
DE60033809T2 (de) * 1999-06-04 2007-12-06 Astrazeneca Ab Inhibitoren von metalloproteinasen
SK287071B6 (sk) 2000-02-21 2009-11-05 Astrazeneca Ab Deriváty N-hydroxyformamidov substituované piperidínom a piperazínom, farmaceutická kompozícia, ktorá ich obsahuje, spôsob ich prípravy a ich použitie
GB0119472D0 (en) * 2001-08-09 2001-10-03 Astrazeneca Ab Compounds
WO2003091247A2 (en) * 2002-04-25 2003-11-06 Pharmacia Corporation Piperidinyl-and piperazinyl-sulfonylmethyl hydroxamic acids and their use as protease inhibitors
CA2528317A1 (en) * 2003-06-19 2004-12-29 Celltech R & D Limited Hydroxamate sulfonamides as cd23 shedding inhibitors

Also Published As

Publication number Publication date
HRP20090009T3 (en) 2009-02-28
US7485644B2 (en) 2009-02-03
UY28387A1 (es) 2005-01-31
EP1644340A1 (en) 2006-04-12
JP2007516164A (ja) 2007-06-21
HK1086835A1 (en) 2006-09-29
DE602004017733D1 (de) 2008-12-24
JP4701167B2 (ja) 2011-06-15
CN102229589A (zh) 2011-11-02
NO20060444L (no) 2006-03-22
US20070197542A1 (en) 2007-08-23
RU2005141058A (ru) 2006-07-27
ES2315675T3 (es) 2009-04-01
ZA200510458B (en) 2007-03-28
IL172615A0 (en) 2006-04-10
MY138680A (en) 2009-07-31
CY1108757T1 (el) 2014-04-09
AU2004251104A1 (en) 2005-01-06
AR044931A1 (es) 2005-10-12
RU2351595C2 (ru) 2009-04-10
PT1644340E (pt) 2009-01-02
CN1812974A (zh) 2006-08-02
SI1644340T1 (sl) 2009-02-28
BRPI0411929A (pt) 2006-08-15
CO5650254A2 (es) 2006-06-30
PL1644340T3 (pl) 2009-04-30
NZ544208A (en) 2009-02-28
SA04250224B1 (ar) 2009-05-31
CN1812974B (zh) 2011-06-29
IS8257A (is) 2006-01-23
WO2005000822A1 (en) 2005-01-06
MXPA05013460A (es) 2006-03-09
KR20060026440A (ko) 2006-03-23
TW200524898A (en) 2005-08-01
SE0301922D0 (sv) 2003-06-27
ATE414063T1 (de) 2008-11-15
DK1644340T3 (da) 2009-02-02
AU2004251104B2 (en) 2008-05-08
CA2529468A1 (en) 2005-01-06
EP1644340B1 (en) 2008-11-12

Similar Documents

Publication Publication Date Title
ES2368013T3 (es) Derivados de hidantoína usados como inhibidores de mmp.
TWI453017B (zh) （２ｓ）－２－（｛３’－氯－４’－〔（２，２－二甲基吡咯烷－１－基）羰基〕－５－氟聯苯－２－基｝氧）丙酸及其藥學上可接受之鹽類
JP5042849B2 (ja) メタロプロテイナーゼ阻害剤として有用なヒダントイン誘導体
ES2311153T3 (es) Derivados de piperidina para el tratamiento de enfermedades mediadas por quimioquina o h1.
JP2012526093A (ja) 置換１−シアノエチルヘテロシクリルカルボキサミド化合物７５０
UA78502C2 (en) Metalloproteinase inhibitors, use thereof, and pharmaceutical composition based thereon
EP3174877B1 (en) Indolizine derivatives which are applicable to neurodegenerative diseases
JP6692759B2 (ja) 新規キノリン誘導体及び神経変性疾患におけるそれらの使用
EP1458676A2 (en) Compounds for the treatment of inflammatory disorders
UA81491C2 (en) N-{'4-substituted piperazine-1-sulfonylmethyl]alkyl}-n-hydroxyformamide compounds as metalloproteinase inhibitors, pharmaceutical composition based thereon, proces for the preparation thereof, intermediate (variants)
BRPI0613563A2 (pt) novos derivados de piperidina
WO2004024060A2 (en) Metalloproteinase inhibitors and intermediates for preparation thereof
JP2012512153A (ja) （４−ｔｅｒｔ−ブチルピペラジン−２−イル）（ピペラジン−１−イル）メタノン−Ｎ−カルボキサミド誘導体